|
OMS causes a sudden inability in a child's capacity to talk, sit or walk. The disease is triggered by a childhood brain tumor called neuroblastoma. The SIU studies may develop new therapies for OMS in children. A three-year grant was awarded by the Thrasher Research Fund to study cytokines as biomarkers and therapeutic targets in paraneoplastic OMS. The total budget of the grant is $279,836. A one-year grant was awarded by Questcor Pharmaceuticals, Inc. to analyze the immunological response to adrenocorticotrophic hormone (ACTH), a drug used in treating OMS. The total budget for the grant is $144,386. Another one-year grant was awarded by Genentech/Biogen IDEC to study how the drug, rituximab, alters inflammation in pediatric OMS. The total budget for the grant is $99,740. A third one-year grant was awarded by the Chicago Institute of Neurosurgery and Neuroresearch Foundation to study lymphocyte cytokine receptors in OMS. The total budget of the grant is $54,400. Pranzatelli's research of pediatric myoclonus has received national funding for more than twenty years and now totals more than $3.7 million. Pranzatelli joined the SIU faculty in 1999. He is director of the National Pediatric Myoclonus Center based at SIU and a member of the medical team at St. John's Children's Hospital. He was a research fellow in neuropharmacology at Children's Hospital of Los Angeles at the University of Southern California from 1982-85, and NIH postdoctoral trainee at the Pediatric Stolinsky Laboratory in 1981-82. Pranzatelli completed his residency in pediatric neurology at the University of Colorado in 1982 and a residency in pediatrics at Case Western Reserve University in 1979. He earned his medical degree from Pennsylvania State University in 1976 and his bachelor's degree at Duquesne University in 1968.
|
|||||
| Return to Home Page | |||||